Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Association of human myxovirus resistance protein A with severity of COVID-19

Fig. 2

Treatment outcome according to initial levels of human myxovirus resistance protein A. A Highest level of respiratory support in patients with low (< 400 μg/L), intermediate (400–799 μg/L) or high (≥ 800 μg/L) initial MxA. B Systemic corticosteroid treatment applied in patients with low, intermediate and high initial MxA. Statistical significance was tested with Pearson’s chi-squared test. MxA human myxovirus resistance protein A; n.s. not significant

Back to article page